BrainChip (BRN) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
6 Apr, 2026Executive summary
2024 marked significant innovation in AI, with BrainChip advancing edge AI through Akida IP and proprietary TENNs models, securing commercial wins with major organizations in aerospace, defense, and research sectors.
The company expanded its patent portfolio, strengthened its engineering and executive teams, and established a Scientific Advisory Board.
Entering 2025, the organization is focused on capitalizing on its robust product roadmap and intensifying operational rigor to drive further market adoption and revenue growth.
Financial highlights
Net loss after tax for 2024 was $24.43M, an improvement from $28.88M in 2023.
Revenue increased 72% year-over-year to $398K, but fell short of significant license and product revenue growth targets.
Operating expenses decreased 17% to $23.87M, with R&D expenses up 9% and G&A expenses up 7%.
Share-based payment expense dropped 52% to $5.45M.
Cash and cash equivalents at year-end were $20M, up from $14.34M in 2023.
Outlook and guidance
The company expects to further develop the Akida Neuromorphic SoC and continue expanding its edge AI product offerings.
2025 will focus on building on 2024 achievements, targeting more commercial wins and broader technology adoption.
Latest events from BrainChip
- Cash outflows improved as AKD1500 production scaled and new commercial partnerships expanded.BRN
Q4 2026 - AGM focused on product innovation, commercial growth, and shareholder engagement challenges.BRN
AGM 2025 - Cash outflows improved, R&D consolidated, and new collaborations drive commercialization efforts.BRN
Q2 2024 - Strategic growth, new edge AI products, and governance dominated, with robust shareholder engagement.BRN
AGM 2026 - Revenue up 374% to $1.89M, net loss narrows, AKD1500 enters production, capital base strengthened.BRN
H2 2025 - Cash position strengthened and new partnerships drive momentum for neuromorphic AI products.BRN
Q4 2025 - Cash balance rose to $13.9M as AKD1500 enters volume production, backed by new capital and partnerships.BRN
Q3 2025 - $35M placement and $2M SPP to accelerate edge AI commercialization and product expansion.BRN
Investor Presentation - Edge AI and neuromorphic solutions drive growth across defense, healthcare, and consumer markets.BRN
Investor Presentation